Abstract
Mesenchymal stem cells (MSC) are capable of differentiating into cells of multiple cell lineages and have potent paracrine effects. Due to their easy preparation and low immunogenicity, MSC have emerged as an extremely promising therapeutic agent in regenerative medicine for diverse diseases. However, MSC are heterogeneous with respect to phenotype and function in current isolation and cultivation regimes, which often lead to incomparable experimental results. In addition, there may be specific stem cell subpopulations with definite differentiation capacity toward certain lineages in addition to stem cells with multi-differentiation potential. Recent studies have identified several subsets of MSC which exhibit distinct features and biological activities, and enhanced therapeutic potentials for certain diseases. In this review, we give an overview of these subsets for their phenotypic, biological and functional properties.
Similar content being viewed by others
References
Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970) The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3(4):393–403
Dmitrieva RI, Minullina IR, Bilibina AA et al (2012) Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: differences and similarities. Cell Cycle 11(2):377–383. doi:10.4161/cc.11.2.18858
Soncini M, Vertua E, Gibelli L et al (2007) Isolation and characterization of mesenchymal cells from human fetal membranes. J Tissue Eng Regen Med 1(4):296–305. doi:10.1002/term.40
Yang ZX, Han ZB, Ji YR et al (2013) CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One 8(3):e59354. doi:10.1371/journal.pone.0059354
Xu J, Liao W, Gu D et al (2009) Neural ganglioside GD2 identifies a subpopulation of mesenchymal stem cells in umbilical cord. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 23(4–6):415–424. doi:10.1159/000218188
Pittenger MF, Mackay AM, Beck SC et al (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143–147
Phinney DG, Prockop DJ (2007) Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair–current views. Stem Cells 25(11):2896–2902. doi:10.1634/stemcells.2007-0637
Liechty KW, MacKenzie TC, Shaaban AF et al (2000) Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6(11):1282–1286. doi:10.1038/81395
Lin RZ, Moreno-Luna R, Li D et al (2014) Human endothelial colony-forming cells serve as trophic mediators for mesenchymal stem cell engraftment via paracrine signaling. Proc Natl Acad Sci USA 111(28):10137–10142. doi:10.1073/pnas.1405388111
Wu Y, Chen L, Scott PG et al (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25(10):2648–2659. doi:10.1634/stemcells.2007-0226
Wu Y, Zhao RC, Tredget EE (2010) Concise review: bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 28(5):905–915. doi:10.1002/stem.420
Chamberlain J, Yamagami T, Colletti E et al (2007) Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 46(6):1935–1945. doi:10.1002/hep.21899
Tamai K, Yamazaki T, Chino T et al (2011) PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA 108(16):6609–6614. doi:10.1073/pnas.1016753108
Parekkadan B, Milwid JM (2010) Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 12:87–117. doi:10.1146/annurev-bioeng-070909-105309
Kim YS, Park EH, Kim YC et al (2013) Clinical outcomes of mesenchymal stem cell injection with arthroscopic treatment in older patients with osteochondral lesions of the talus. Am J Sports Med 41(5):1090–1099. doi:10.1177/0363546513479018
Trounson A, McDonald C (2015) Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 17(1):11–22. doi:10.1016/j.stem.2015.06.007
Lv FJ, Tuan RS, Cheung KM et al (2014) Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 32(6):1408–1419. doi:10.1002/stem.1681
Rostovskaya M, Anastassiadis K (2012) Differential expression of surface markers in mouse bone marrow mesenchymal stromal cell subpopulations with distinct lineage commitment. PLoS One 7(12):e51221. doi:10.1371/journal.pone.0051221
Dominici M, Le Blanc K, Mueller I et al (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315–317. doi:10.1080/14653240600855905
Phinney DG (2012) Functional heterogeneity of mesenchymal stem cells: implications for cell therapy. J Cell Biochem 113(9):2806–2812. doi:10.1002/jcb.24166
Tormin A, Brune JC, Olsson E et al (2009) Characterization of bone marrow-derived mesenchymal stromal cells (MSC) based on gene expression profiling of functionally defined MSC subsets. Cytotherapy 11(2):114–128. doi:10.1080/14653240802716590
Arufe MC, De la Fuente A, Fuentes I et al (2010) Chondrogenic potential of subpopulations of cells expressing mesenchymal stem cell markers derived from human synovial membranes. J Cell Biochem 111(4):834–845. doi:10.1002/jcb.22768
Colter DC, Sekiya I, Prockop DJ (2001) Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci USA 98(14):7841–7845. doi:10.1073/pnas.141221698
Prockop DJ, Sekiya I, Colter DC (2001) Isolation and characterization of rapidly self-renewing stem cells from cultures of human marrow stromal cells. Cytotherapy 3(5):393–396. doi:10.1080/146532401753277229
Lee RH, Hsu SC, Munoz J et al (2006) A subset of human rapidly self-renewing marrow stromal cells preferentially engraft in mice. Blood 107(5):2153–2161. doi:10.1182/blood-2005-07-2701
Iinuma S, Aikawa E, Tamai K et al (2015) Transplanted bone marrow-derived circulating PDGFRalpha+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol 194(4):1996–2003. doi:10.4049/jimmunol.1400914
Mabuchi Y, Morikawa S, Harada S et al (2013) LNGFR(+)THY-1(+)VCAM-1(hi +) cells reveal functionally distinct subpopulations in mesenchymal stem cells. Stem cell reports 1(2):152–165. doi:10.1016/j.stemcr.2013.06.001
Seeger FH, Rasper T, Koyanagi M et al (2009) CXCR4 expression determines functional activity of bone marrow-derived mononuclear cells for therapeutic neovascularization in acute ischemia. Arterioscler Thromb Vasc Biol 29(11):1802–1809. doi:10.1161/ATVBAHA.109.194688
Lane SW, Williams DA, Watt FM (2014) Modulating the stem cell niche for tissue regeneration. Nat Biotech 32(8):795–803. doi:10.1038/nbt.2978
Jiang Y, Jahagirdar BN, Reinhardt RL et al (2002) Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893):41–49. doi:10.1038/nature00870
Kuroda Y, Kitada M, Wakao S et al (2010) Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci USA 107(19):8639–8643. doi:10.1073/pnas.0911647107
Han B, Li J, Li Z et al (2013) Trichostatin A stabilizes the expression of pluripotent genes in human mesenchymal stem cells during ex vivo expansion. PLoS One 8(11):e81781. doi:10.1371/journal.pone.0081781
Li Z, Liu C, Xie Z et al (2011) Epigenetic dysregulation in mesenchymal stem cell aging and spontaneous differentiation. PLoS One 6(6):e20526. doi:10.1371/journal.pone.0020526
Ning H, Lin G, Lue TF et al (2011) Mesenchymal stem cell marker Stro-1 is a 75 kd endothelial antigen. Biochem Biophys Res Comm 413(2):353–357. doi:10.1016/j.bbrc.2011.08.104
Lin G, Liu G, Banie L et al (2011) Tissue distribution of mesenchymal stem cell marker Stro-1. Stem Cells Dev 20(10):1747–1752. doi:10.1089/scd.2010.0564
Psaltis PJ, Paton S, See F et al (2010) Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol 223(2):530–540. doi:10.1002/jcp.22081
Bensidhoum M, Chapel A, Francois S et al (2004) Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 103(9):3313–3319. doi:10.1182/blood-2003-04-1121
Samsonraj RM, Rai B, Sathiyanathan P et al (2015) Establishing criteria for human mesenchymal stem cell potency. Stem Cells 33(6):1878–1891. doi:10.1002/stem.1982
Zannettino AC, Paton S, Kortesidis A et al (2007) Human mulipotential mesenchymal/stromal stem cells are derived from a discrete subpopulation of STRO-1bright/CD34/CD45(-)/glycophorin-A-bone marrow cells. Haematologica 92(12):1707–1708. doi:10.3324/haematol.11691
Simmons PJ, Torokstorb B (1991) Identification of stromal cell precursors in human bone-marrow by a novel monoclonal-antibody, Stro-1. Blood 78(1):55–62
Martens TP, See F, Schuster MD et al (2006) Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. Nature Clin Pract Cardiovasc Med 3(Suppl 1):S18–S22. doi:10.1038/ncpcardio0404
Thomson TM, Rettig WJ, Chesa PG et al (1988) Expression of human nerve growth factor receptor on cells derived from all three germ layers. Exp Cell Res 174(2):533–539
Busser H, Najar M, Raicevic G et al (2015) Isolation and characterization of human mesenchymal stromal cell subpopulations: comparison of bone marrow and adipose tissue. Stem Cells Dev 24(18):2142–2157. doi:10.1089/scd.2015.0172
Quirici N, Soligo D, Bossolasco P et al (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. Exp Hematol 30(7):783–791
Iso Y, Yamaya S, Sato T et al (2012) Distinct mobilization of circulating CD271+ mesenchymal progenitors from hematopoietic progenitors during aging and after myocardial infarction. Stem Cells Transl Med 1(6):462–468. doi:10.5966/sctm.2011-0051
Cuthbert R, Boxall SA, Tan HB et al (2012) Single-platform quality control assay to quantify multipotential stromal cells in bone marrow aspirates prior to bulk manufacture or direct therapeutic use. Cytotherapy 14(4):431–440. doi:10.3109/14653249.2011.651533
Cuthbert RJ, Giannoudis PV, Wang XN et al (2015) Examining the feasibility of clinical grade CD271+ enrichment of mesenchymal stromal cells for bone regeneration. PLoS One 10(3):e0117855. doi:10.1371/journal.pone.0117855
Churchman SM, Ponchel F, Boxall SA et al (2012) Transcriptional profile of native CD271+ multipotential stromal cells: evidence for multiple fates, with prominent osteogenic and Wnt pathway signaling activity. Arthritis Rheum 64(8):2632–2643. doi:10.1002/art.34434
Mifune Y, Matsumoto T, Murasawa S et al (2013) Therapeutic superiority for cartilage repair by CD271-positive marrow stromal cell transplantation. Cell Transplant 22(7):1201–1211. doi:10.3727/096368912X657378
Kuci S, Kuci Z, Kreyenberg H et al (2010) CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 95(4):651–659. doi:10.3324/haematol.2009.015065
Li H, Ghazanfari R, Zacharaki D et al (2014) Low/negative expression of PDGFR-alpha identifies the candidate primary mesenchymal stromal cells in adult human bone marrow. Stem Cell Report 3(6):965–974. doi:10.1016/j.stemcr.2014.09.018
Battula VL, Treml S, Bareiss PM et al (2009) Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1. Haematologica 94(2):173–184. doi:10.3324/haematol.13740
Noort WA, Oerlemans MI, Rozemuller H et al (2012) Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. J Cell Mol Med 16(8):1827–1839. doi:10.1111/j.1582-4934.2011.01455.x
Latifi-Pupovci H, Kuci Z, Wehner S et al (2015) In vitro migration and proliferation (“wound healing”) potential of mesenchymal stromal cells generated from human CD271(+) bone marrow mononuclear cells. J Transl Med 13:315. doi:10.1186/s12967-015-0676-9
Duff SE, Li C, Garland JM et al (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J Off Publ Fed Am Soc Exp Biol 17(9):984–992. doi:10.1096/fj.02-0634rev
Gaebel R, Furlani D, Sorg H et al (2011) Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS One 6(2):e15652. doi:10.1371/journal.pone.0015652
Pierelli L, Bonanno G, Rutella S et al (2001) CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymph 42(6):1195–1206. doi:10.3109/10428190109097744
Noiseux N, Gnecchi M, Lopez-Ilasaca M et al (2006) Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther J Am Soc Gene Ther 14(6):840–850. doi:10.1016/j.ymthe.2006.05.016
Silva GV, Litovsky S, Assad JA et al (2005) Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111(2):150–156. doi:10.1161/01.CIR.0000151812.86142.45
Conconi MT, Burra P, Di Liddo R et al (2006) CD105(+) cells from Wharton’s jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med 18(6):1089–1096
Roura S, Farre J, Soler-Botija C et al (2006) Effect of aging on the pluripotential capacity of human CD105 +mesenchymal stem cells. Eur J Heart Fail 8(6):555–563. doi:10.1016/j.ejheart.2005.11.006
Ranganath SH, Levy O, Inamdar MS et al (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10(3):244–258. doi:10.1016/j.stem.2012.02.005
Li N, Wang C, Jia L et al (2014) Heart regeneration, stem cells, and cytokines. Regen Med Res 2(1):6. doi:10.1186/2050-490X-2-6
Iohara K, Imabayashi K, Ishizaka R et al (2011) Complete pulp regeneration after pulpectomy by transplantation of CD105 + stem cells with stromal cell-derived factor-1. Tissue Eng Part A 17(15–16):1911–1920. doi:10.1089/ten.TEA.2010.0615
Pettine KA, Murphy MB, Suzuki RK et al (2015) Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cell 33(1):146–156. doi:10.1002/stem.1845
Alon R, Kassner PD, Carr MW et al (1995) The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 128(6):1243–1253
Schaffler A, Buchler C (2007) Concise review: adipose tissue-derived stromal cells–basic and clinical implications for novel cell-based therapies. Stem Cell 25(4):818–827. doi:10.1634/stemcells.2006-0589
Fukiage K, Aoyama T, Shibata KR et al (2008) Expression of vascular cell adhesion molecule-1 indicates the differentiation potential of human bone marrow stromal cells. Biochem Biophys Res Comm 365(3):406–412. doi:10.1016/j.bbrc.2007.10.149
Gronthos S, Zannettino AC, Hay SJ et al (2003) Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 116(Pt 9):1827–1835
Fujita R, Tamai K, Aikawa E et al (2015) Endogenous mesenchymal stromal cells in bone marrow are required to preserve muscle function in mdx mice. Stem Cell 33(3):962–975. doi:10.1002/stem.1900
Ren G, Zhao X, Zhang L et al (2010) Inflammatory Cytokine-Induced Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 in Mesenchymal Stem Cells Are Critical for Immunosuppression. J Immunol 184(5):2321–2328. doi:10.4049/jimmunol.0902023
Castro-Manrreza ME, Montesinos JJ (2015) Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res 2015:394917. doi:10.1155/2015/394917
Shih IM (1999) The role of CD146 (Mel-CAM) in biology and pathology. J Pathol 189(1):4–11. doi:10.1002/(SICI)1096-9896(199909)189:1<4:AID-PATH332>3.0.CO;2-P
Martin-Rendon E, Sweeney D, Lu F et al (2008) 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang 95(2):137–148. doi:10.1111/j.1423-0410.2008.01076.x
Rider DA, Dombrowski C, Sawyer AA et al (2008) Autocrine fibroblast growth factor 2 increases the multipotentiality of human adipose-derived mesenchymal stem cells. Stem Cells 26(6):1598–1608. doi:10.1634/stemcells.2007-0480
Maleki M, Ghanbarvand F, Reza Behvarz M et al (2014) Comparison of mesenchymal stem cell markers in multiple human adult stem cells. Int J Stem Cell 7(2):118–126. doi:10.15283/ijsc.2014.7.2.118
Espagnolle N, Guilloton F, Deschaseaux F et al (2014) CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med 18(1):104–114. doi:10.1111/jcmm.12168
Crisan M, Yap S, Casteilla L et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301–313. doi:10.1016/j.stem.2008.07.003
Sacchetti B, Funari A, Michienzi S et al (2007) Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131(2):324–336. doi:10.1016/j.cell.2007.08.025
Blocki A, Wang Y, Koch M et al (2013) Not all MSCs can act as pericytes: functional in vitro assays to distinguish pericytes from other mesenchymal stem cells in angiogenesis. Stem Cells Dev 22(17):2347–2355. doi:10.1089/scd.2012.0415
Caplan AI (2008) All MSCs are pericytes? Cell Stem Cell 3(3):229–230. doi:10.1016/j.stem.2008.08.008
Baksh D, Yao R, Tuan RS (2007) Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25(6):1384–1392. doi:10.1634/stemcells.2006-0709
Russell KC, Phinney DG, Lacey MR et al (2010) In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cell 28(4):788–798. doi:10.1002/stem.312
Sorrentino A, Ferracin M, Castelli G et al (2008) Isolation and characterization of CD146 + multipotent mesenchymal stromal cells. Exp Hematol 36(8):1035–1046. doi:10.1016/j.exphem.2008.03.004
Corselli M, Chin CJ, Parekh C et al (2013) Perivascular support of human hematopoietic stem/progenitor cells. Blood 121(15):2891–2901. doi:10.1182/blood-2012-08-451864
Park TS, Gavina M, Chen CW et al (2011) Placental perivascular cells for human muscle regeneration. Stem Cell Dev 20(3):451–463. doi:10.1089/scd.2010.0354
Chen CW, Okada M, Proto JD et al (2013) Human pericytes for ischemic heart repair. Stem Cell 31(2):305–316. doi:10.1002/stem.1285
Houlihan DD, Mabuchi Y, Morikawa S et al (2012) Isolation of mouse mesenchymal stem cells on the basis of expression of Sca-1 and PDGFR-α. Nat Protoc 7(12):2103–2111. doi:10.1038/nprot.2012.125
Hoffman AM, Paxson JA, Mazan MR et al (2011) Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung. Stem Cell Dev 20(10):1779–1792. doi:10.1089/scd.2011.0105
Jiang MH, Li G, Liu J et al (2015) Nestin(+) kidney resident mesenchymal stem cells for the treatment of acute kidney ischemia injury. Biomaterials 50:56–66. doi:10.1016/j.biomaterials.2015.01.029
Morikawa S, Mabuchi Y, Kubota Y et al (2009) Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 206(11):2483–2496. doi:10.1084/jem.20091046
Pinho S, Lacombe J, Hanoun M et al (2013) PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med 210(7):1351–1367. doi:10.1084/jem.20122252
Fathke C, Wilson L, Hutter J et al (2004) Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cell 22(5):812–822. doi:10.1634/stemcells.22-5-812
Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22(10):1276–1312. doi:10.1101/gad.1653708
Hellstrom M, Kalen M, Lindahl P et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126(14):3047–3055
Ball SG, Shuttleworth CA, Kielty CM (2007) Platelet-derived growth factor receptor-alpha is a key determinant of smooth muscle alpha-actin filaments in bone marrow-derived mesenchymal stem cells. Int J Biochem Cell Biol 39(2):379–391. doi:10.1016/j.biocel.2006.09.005
Ball SG, Shuttleworth A, Kielty CM (2012) Inhibition of platelet-derived growth factor receptor signaling regulates Oct4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cell 30(3):548–560. doi:10.1002/stem.1015
Rajkumar VS, Shiwen X, Bostrom M et al (2006) Platelet-Derived Growth Factor-β Receptor Activation Is Essential for Fibroblast and Pericyte Recruitment during Cutaneous Wound Healing. Am J Pathol 169(6):2254–2265. doi:10.2353/ajpath.2006.060196
Tokunaga A, Oya T, Ishii Y et al (2008) PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res Off J Am Soc Bone Miner Res 23(9):1519–1528. doi:10.1359/jbmr.080409
Tigges U, Komatsu M, Stallcup WB (2013) Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury. J Vasc Res 50(2):134–144. doi:10.1159/000345524000345524
Ball SG, Worthington JJ, Canfield AE et al (2014) Mesenchymal stromal cells: inhibiting PDGF receptors or depleting fibronectin induces mesodermal progenitors with endothelial potential. Stem Cell 32(3):694–705. doi:10.1002/stem.1538
Lendahl U, Zimmerman LB, McKay RD (1990) CNS stem cells express a new class of intermediate filament protein. Cell 60(4):585–595
Mendez-Ferrer S, Michurina TV, Ferraro F et al (2010) Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 466(7308):829–834. doi:10.1038/nature09262
Isern J, Martin-Antonio B, Ghazanfari R et al (2013) Self-renewing human bone marrow mesenspheres promote hematopoietic stem cell expansion. Cell Report 3(5):1714–1724. doi:10.1016/j.celrep.2013.03.041
Wan M, Li C, Zhen G et al (2012) Injury-activated transforming growth factor beta controls mobilization of mesenchymal stem cells for tissue remodeling. Stem Cells 30(11):2498–2511. doi:10.1002/stem.1208
Zhen G, Wen C, Jia X et al (2013) Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med 19(6):704–712. doi:10.1038/nm.3143
Follenzi A, Raut S, Merlin S et al (2012) Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 119(23):5532–5542. doi:10.1182/blood-2011-07-367680
Ip JE, Wu Y, Huang J et al (2007) Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell 18(8):2873–2882. doi:10.1091/mbc.E07-02-0166
Shi M, Li J, Liao L et al (2007) Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematol-Hematol J 92(7):897–904. doi:10.3324/haematol.10669
Potapova IA, Brink PR, Cohen IS et al (2008) Culturing of human mesenchymal stem cells as three-dimensional aggregates induces functional expression of CXCR4 that regulates adhesion to endothelial cells. J Biol Chem 283(19):13100–13107. doi:10.1074/jbc.M800184200
Liu H, Liu S, Li Y et al (2012) The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 7(4):e34608. doi:10.1371/journal.pone.0034608
Cheng Z, Ou L, Zhou X et al (2008) Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther J Am Soc Gene Ther 16(3):571–579. doi:10.1038/sj.mt.6300374
Wang Z, Wang Y, Wang Z et al (2015) Engineered mesenchymal stem cells with enhanced tropism and paracrine secretion of cytokines and growth factors to treat traumatic brain injury. Stem Cell 33(2):456–467. doi:10.1002/stem.1878
Yu Q, Liu L, Lin J et al (2015) SDF-1alpha/CXCR4 Axis Mediates The Migration of Mesenchymal Stem Cells to The Hypoxic-Ischemic Brain Lesion in A Rat Model. Cell J 16(4):440–447
Du Z, Wei C, Yan J et al (2013) Mesenchymal stem cells overexpressing C-X-C chemokine receptor type 4 improve early liver regeneration of small-for-size liver grafts. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc 19(2):215–225. doi:10.1002/lt.23577
Gang EJ, Bosnakovski D, Figueiredo CA et al (2007) SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109(4):1743–1751. doi:10.1182/blood-2005-11-010504
Hamamoto H, Gorman JH 3rd, Ryan LP et al (2009) Allogeneic mesenchymal precursor cell therapy to limit remodeling after myocardial infarction: the effect of cell dosage. Annals Thorac Surg 87(3):794–801. doi:10.1016/j.athoracsur.2008.11.057
Ortiz LA, Dutreil M, Fattman C et al (2007) Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 104(26):11002–11007. doi:10.1073/pnas.0704421104
Herrera MB, Bussolati B, Bruno S et al (2007) Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72(4):430–441. doi:10.1038/sj.ki.5002334
Lee RH, Seo MJ, Pulin AA et al (2009) The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 113(4):816–826. doi:10.1182/blood-2007-12-128702
Zhou BO, Yue R, Murphy MM et al (2014) Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 15(2):154–168. doi:10.1016/j.stem.2014.06.008
Acknowledgments
This work was supported by grants from Natural Science Foundation of China (No. 31371404, 31571429), Natural Science Foundation of Guangdong (2015A030311041), and Shenzhen Science and Technology Innovation Committee (JCYJ20140417115840279, GJHZ20150316160614842).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Mo, M., Wang, S., Zhou, Y. et al. Mesenchymal stem cell subpopulations: phenotype, property and therapeutic potential. Cell. Mol. Life Sci. 73, 3311–3321 (2016). https://doi.org/10.1007/s00018-016-2229-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-016-2229-7